Page last updated: 2024-10-24

chloroquine and Acute Rheumatic Fever

chloroquine has been researched along with Acute Rheumatic Fever in 25 studies

Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.

Research

Studies (25)

TimeframeStudies, this research(%)All Research%
pre-199023 (92.00)18.7374
1990's0 (0.00)18.2507
2000's2 (8.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
RODRIGUE, C1
Abud-Mendoza, C1
de la Fuente, H1
Cuevas-Orta, E1
Baranda, L1
Cruz-Rizo, J1
González-Amaro, R1
FORESTIER, J1
CERTONCINY, A1
GUENTHER, R1
OGUNI, S1
OKAMOTO, Y1
MATSUO, J1
YABUTA, K1
KADOMA, K1
KOVACS, L1
KOSZTOLNYIK, J1
TAKACS, B1
GAAL, K1
FORD, DK1
STEPAN, J3
KAKAC, B1
BYWATERS, EG1
MARKIEWICZ, K1
KRALOVA, M1
VOJTISEK, O1
MARSIKOVA, L1
PROKOPOVA, D1
KERUZORE, A1
COSTE, F1
DELBARRE, F1
LOUYOT, P1
GAUCHER, A1
MATHIEU, J1
METZ, R1
El aichaoui, S1
Amine, B1
Saoud, B1
Guedira, N1
Allali, F1
Hajjaj-Hassouni, N1
Wirth, W1
Diekmann, L1
Klokenbusch, S1
Skorobatskiĭ, VS1
Dolgopolova, AV1
Reuschel, I1
Reinelt, D1
Gruber, G1
Sigidin, IaA2
Lendle, L1
Bibikova, TI1
Hrncír, Z1
Nesterov, AJ1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Double Blind, Placebo Controlled, Phase II, Randomized Study of Lovastatin Therapy in the Treatment of Mildly Active Rheumatoid Arthritis[NCT00302952]Phase 264 participants (Actual)Interventional2007-11-06Terminated (stopped due to Slow enrollment &Study Drug Expiration (Target: 40 randomized participants /arm))
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Adjusted Mean Change From Baseline in Log Transformed C - Reactive Protein (CRP) at Day 84

Blood draw for CRP, an acute phase reactant used to identify the presence of nonspecific inflammation. Change=Day 84 value minus Baseline value. Normal serum CRP reference range in this study is 0-4 mg/L (log transformed: -4.2 to 1.4). Participants with measurements for designated time points were included in analysis. An increased CRP level indicates the presence of inflammation. Reduced CRP levels could mean a decrease in inflammation. (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)

Interventionmg/L (Mean)
Lovastatin 80 mg-0.4
Placebo-0.3

Adjusted Mean Change From Baseline in Serum Anti-cyclic Citrullinated Peptide (Anti-CCP) by ELISA (ELISA: Enzyme-linked Immunosorbent Assay)

Anti-CCP antibodies are autoantibodies frequently detected in the serum of individuals with rheumatoid arthritis. In this study, a positive value for anti-CCP was 8 IU/mL or greater; a negative value for anti-CCP was <8 IU/mL. Change= subtraction of Day 0 from Day 84 anti-CCP value. In general, high levels of the antibody indicate an aggressive rheumatoid arthritis and a higher risk of joint damage. Participants with measurements for designated time points included in analysis. (NCT00302952)
Timeframe: Baseline ( Day 0), Day 84 (Wk 12)

InterventionIU/mL (Mean)
Lovastatin 80 mg16.3
Placebo-1.0

Adjusted Mean Change From Baseline in Serum IgM Rheumatoid Factor by ELISA (ELISA: Enzyme-linked Immunosorbent Assay)

Rheumatoid factor (RF) is an antibody often present in the blood of a person with rheumatoid arthritis. In this study, a positive value for RF was 0.5 IU/mL or greater; a negative value for RF was <0.5 IU/mL. Change= Day 84 value minus Baseline value. In general, presence of the antibody indicates aggressive rheumatoid arthritis and higher risk of joint damage. Participants with measurements for designated time points included in analysis. (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)

InterventionIU/mL (Mean)
Lovastatin 80 mg-5.4
Placebo2.8

Adjusted Mean Change From Baseline in the Disease Activity Score Using C-reactive Protein (DAS28-CRP) on Day 84

The DAS28-CRP score is on a scale of 0 to 10 and indicates current activity of rheumatoid arthritis (>5.1=high disease activity; 3.2-<=5.1=moderate disease activity; <=3.2=low disease activity; <2.6=remission). The score uses a combination of four variables: 1) the number of tender joints (of the 28 that are measured); 2) the number of swollen joints (of the 28 that are measured); 3) serum C-reactive protein (CRP) lab value in mg/L , and 4) Patient Global Assessment of Disease Activity. Using a formula, the physician determines the score. Participants with measurements for designated time points included in analysis. (NCT00302952)
Timeframe: Baseline (Day 0) to Day 84 (Wk 12)

InterventionScores on a scale (Mean)
Lovastatin 80 mg-0.5
Placebo-0.5

Change From Baseline in CPK at Day 84

Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)

InterventionU/L (Mean)
Lovastatin 80 mg-2.4
Placebo8.0

Change From Baseline in Hematocrit (Hct) at Day 84

Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)

Intervention% of packed red blood cells by volume (Mean)
Lovastatin 80 mg-0.5
Placebo-0.5

Change From Baseline in Mean Corpuscular Hemoglobin (MCH) at Day 84

Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)

Interventionpg (Mean)
Lovastatin 80 mg-0.4
Placebo0.0

Change From Baseline in Mean Corpuscular Volume (MCV) at Day 84

Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)

InterventionfL (Mean)
Lovastatin 80 mg-0.4
Placebo0.7

Change From Baseline in Red Cell Distribution Width (RDW) at Day 84

Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)

Intervention% of mean corpuscle volume (Mean)
Lovastatin 80 mg-0.4
Placebo0.2

Percentage of Participants Meeting ACR20 Response Criteria at Day 84 (ACR: American College of Rheumatology)

Patients were ACR20 Responders if they had: at least 20% improvement in both tender joint count (28 examined) and swollen joint count (28 examined), and 20% improvement in at least three of the following 5 remaining ACR core measures: • Patient's pain assessment (Visual Analogue Scale (VAS) 100 mm) • Patient's global assessment of disease activity (VAS 100 mm) • Physician's global assessment of disease activity (VAS 100 mm) • Patient self-assessed disability (Health Assessment Questionnaire (HAQ)) score • Acute phase reactant C-reactive protein. Participants with measurements for designated time points were included in analysis. (NCT00302952)
Timeframe: Day 84 (Wk 12)

InterventionPercentage of participants (Number)
Lovastatin 80 mg29.0
Placebo40.0

Change From Baseline in Albumin, Total Protein, Hemoglobin, and Mean Corpuscular Hemoglobin Concentration (MCHC) at Day 84

Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)

,
Interventiong/dL (Mean)
AlbuminTotal ProteinHemoglobinMCHC
Lovastatin 80 mg0.00.0-0.3-0.3
Placebo0.10.1-0.3-0.4

Change From Baseline in Alkaline Phosphatase, Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) at Day 84

Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)

,
InterventionU/L (Mean)
Alkaline PhosphataseALTAST
Lovastatin 80 mg-3.0-1.8-1.2
Placebo0.40.70.8

Change From Baseline in Counts: White Blood Cells (WBC), Neutrophils, Bands, Lymphocytes, Monocytes, Eosinophils, Basophils, Platelets, and Reticulocytes at Day 84

Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)

,
Intervention10^3/uL (Mean)
WBCNeutrophilsBandsLymphocytesMonocytesEosinophilsBasophilsPlatelet CountReticulocytes
Lovastatin 80 mg0.10.20.0-0.10.10.00.0-8.2-4.7
Placebo-0.4-0.60.00.10.00.00.0-5.60.0

Change From Baseline in Potassium, Sodium, Chloride, and Total CO2 at Day 84

Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)

,
Interventionmmol/L (Mean)
PotassiumSodiumChlorideTotal CO2
Lovastatin 80 mg0.0-0.2-0.10.7
Placebo0.0-0.20.5-0.5

Change From Baseline in Total Bilirubin, Creatinine, BUN, Phosphorus, Calcium, and Glucose at Day 84

Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html (NCT00302952)
Timeframe: Baseline (Day 0), Day 84 (Wk 12)

,
Interventionmg/dL (Mean)
Total BilirubinCreatinineBUNPhosphorusCalciumGlucose
Lovastatin 80 mg0.00.0-0.40.00.0-4.3
Placebo0.10.0-0.50.00.0-1.2

Trials

2 trials available for chloroquine and Acute Rheumatic Fever

ArticleYear
Therapy with statins in patients with refractory rheumatic diseases: a preliminary study.
    Lupus, 2003, Volume: 12, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Atorvastatin; Biomarkers; Blood Sedimentation;

2003
[On the mechanism of the therapeutic action of antirheumatic preparations].
    Terapevticheskii arkhiv, 1967, Volume: 39, Issue:9

    Topics: Adrenal Cortex Hormones; Chloroquine; Clinical Trials as Topic; Collagen Diseases; Humans; Pyrazoles

1967

Other Studies

23 other studies available for chloroquine and Acute Rheumatic Fever

ArticleYear
Rheumatic fever; clinical and differential diagnosis.
    El Dia medico, 1948, May-03, Volume: 20, Issue:18

    Topics: Chloroquine; Humans; Rheumatic Fever

1948
[Serological research in chronic inflammatory rheumatism; study of antistreptolysin O].
    Revue du rhumatisme et des maladies osteo-articulaires, 1954, Volume: 21, Issue:5

    Topics: Antistreptolysin; Arthritis, Rheumatoid; Chloroquine; Chronic Disease; Humans; Quinacrine; Research;

1954
[On the resochin therapy of primary chronic polyarthritis rheumatica].
    Medizinische Klinik, 1959, Nov-13, Volume: 54

    Topics: Arthritis, Rheumatoid; Chloroquine; Chronic Disease; Rheumatic Fever

1959
[Severe cases of rheumatic fever resistant to normal doses of steroid hormone preparations and methods of management].
    [Chiryo] [Therapy], 1962, Dec-01, Volume: 44

    Topics: Chloroquine; Disease Management; Humans; Prednisolone; Rheumatic Fever; Steroids; Triamcinolone

1962
[Combined cases of Bechterew's disease].
    Magyar belorvosi archivum (1955), 1962, Volume: 15

    Topics: Arthritis; Arthritis, Rheumatoid; Chloroquine; Humans; Prednisolone; Rheumatic Fever; Spondylitis; S

1962
NON-STEROID ANTIRHEUMATIC DRUGS.
    Canadian Medical Association journal, 1964, Sep-19, Volume: 91

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Biomedical Resea

1964
DETERMINATION OF CHLOROQUINE IN URINE BY UV-SPECTROGRAPHY AND THE TYPES OF SPECTRA AFTER INTRAVENOUS INFUSION.
    Medicina experimentalis : International journal of experimental medicine, 1964, Volume: 11

    Topics: Arthritis; Arthritis, Rheumatoid; Chloroquine; Chromatography; Colorimetry; Drug Therapy; Infusions,

1964
[DAMAGE DUE TO LONG-TERM THERAPY. 1. ANTIRHEUMATIC AGENTS].
    Hippokrates, 1964, Jul-31, Volume: 35

    Topics: Adrenal Cortex Hormones; Aminopyrine; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Chloro

1964
CHILD CARE IN GENERAL PRACTICE. RHEUMATIC FEVER AND RHEUMATOID ARTHRITIS.
    British medical journal, 1965, Jun-26, Volume: 1, Issue:5451

    Topics: Adolescent; Arthritis; Arthritis, Juvenile; Arthritis, Rheumatoid; Child; Child Care; Chloroquine; D

1965
[SIDE EFFECTS AND COMPLICATIONS FOLLOWING THE ADMINISTRATION OF QREEHIM].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 1965, Mar-01, Volume: 18

    Topics: Chloroquine; Drug Therapy; Rheumatic Fever; Toxicology

1965
EOSINOPENIA AND ACTH-ELECTROLYTE TEST AFTER CHLOROQUINE DIPHOSPHATE INFUSION IN PATIENTS WITH ARTICULAR DISEASE.
    Medicina et pharmacologia experimentalis. International journal of experimental medicine, 1965, Volume: 12

    Topics: Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumatoid; Chloroquine; Drug Therapy; Electrolyt

1965
ON THE PROBLEM OF THE INTERFERENCE OF CHLOROQUINE WITH THE REGULATORY MECHANISMS IN MAN.
    Medicina et pharmacologia experimentalis. International journal of experimental medicine, 1965, Volume: 12

    Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Arthritis; Arthritis, Rheumatoid; Chloroquine; Drug Therap

1965
[The treatment of inflammatory rheumatism by antimalarials (chloroquine and hydroxychloroquine)].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1960, Apr-04, Volume: 36

    Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Rheumatic Diseases; Rheumatic Fever

1960
[Treatment of chronic inflammatory rheumatism with chloroquine and its derivatives].
    Revue medicale de Nancy, 1961, Volume: 86

    Topics: Arthritis, Rheumatoid; Chloroquine; Chronic Disease; Humans; Rheumatic Diseases; Rheumatic Fever

1961
[Complete auriculoventricular block during chloroquine treatment].
    La Revue de medecine interne, 2007, Volume: 28, Issue:2

    Topics: Adult; Aged; Antirheumatic Agents; Chloroquine; Female; Heart Block; Humans; Pacemaker, Artificial;

2007
[Problems of disseminated lupus erythematosus in infants and children].
    Verhandlungen der Deutschen Gesellschaft fur Rheumatologie, 1978, Volume: 5

    Topics: Arthritis, Rheumatoid; Azathioprine; Child; Child, Preschool; Chloroquine; Dermatomyositis; Female;

1978
[Effect of quinoline derivatives on certain indicators of humoral immunity and streptococcal allergy in rheumatic patients].
    Sovetskaia meditsina, 1974, Volume: 0, Issue:7

    Topics: Adult; Antibodies, Bacterial; Antibody Formation; Antistreptolysin; Chloroquine; Female; Humans; Hya

1974
[Current aspects of treatment and prevention of rheumatic fever in children].
    Voprosy okhrany materinstva i detstva, 1974, Volume: 19, Issue:11

    Topics: Aminopyrine; Aspirin; Benzoates; Child; Chloroquine; Humans; Immunosuppressive Agents; Indomethacin;

1974
[Diagnosis and course evaluation in rheumatic fever].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1974, Sep-15, Volume: 29, Issue:18

    Topics: Acute Disease; Adult; Aminopyrine; Child; Chloroquine; Humans; Penicillins; Phenylbutazone; Predniso

1974
[Critical view on drug therapy for rheumatism].
    Zeitschrift fur Rheumaforschung, 1967, Volume: 26, Issue:11

    Topics: Analgesics; Animals; Anti-Bacterial Agents; Chloroquine; Drug-Related Side Effects and Adverse React

1967
[Results of long-term treatment of rheumatism with resoquine].
    Klinicheskaia meditsina, 1968, Volume: 46, Issue:6

    Topics: Adolescent; Adult; Chloroquine; Female; Humans; Male; Middle Aged; Rheumatic Fever; Time Factors

1968
[Can chloroquine be used in the treatment of rheumatic fever and the prevention of recrudescence?].
    Casopis lekaru ceskych, 1966, Dec-23, Volume: 105, Issue:52

    Topics: Chloroquine; Humans; Rheumatic Fever

1966
[Treatment of rheumatic fever].
    Revista espanola de reumatismo y enfermedades osteoarticulares, 1966, Volume: 11, Issue:7

    Topics: Adrenal Cortex Hormones; Chloroquine; Humans; Pyrazoles; Rheumatic Fever; Rheumatic Heart Disease; S

1966